Fractyl Health reports 1-year Revita results showing durable GLP-1 weight loss maintenance. In 45 participants, weight regain fell to 7.8% versus 13.0% for sham, with greater retention in higher-risk subgroups (81-84%). Responder rates climbed (73% overall; 91% with complete ablation) and safety was comparable to sham. The data could accelerate adoption of post-GLP-1 device therapy, contributing to a near-term stock move for GUTS.
Fractyl Health Inc. (GUTS) experienced a significant stock decline following news of a potential shift in regulatory strategy for its Revita product. This change raises concerns about future approvals and market readiness, which could further influence stock performance in the coming months.
